Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis
Top Cited Papers
Open Access
- 17 May 2000
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 283 (19) , 2537-2545
- https://doi.org/10.1001/jama.283.19.2537
Abstract
The World Health Organization (WHO) tuberculosis (TB) control strategy, directly observed treatment short-course (DOTS), consists of 5 components, including the administration of standardized short-course chemotherapy (SCC) regimens with first-line drugs (isoniazid, rifampicin, pyrazinamide, and streptomycin or ethambutol or both) under direct observation, at least in the intensive treatment phase, regardless of patient drug-susceptibility pattern.1 This strategy, which is considered by the World Bank as one of the most cost-effective interventions in human health,2 has now been adopted by 119 countries worldwide.3Keywords
This publication has 7 references indexed in Scilit:
- Clinical Consequences and Transmissibility of Drug-Resistant Tuberculosis in Southern MexicoArchives of internal medicine (1960), 2000
- First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisonsThe Lancet, 1999
- Global Surveillance for Antituberculosis-Drug Resistance, 1994–1997New England Journal of Medicine, 1998
- Assessment of worldwide tuberculosis controlThe Lancet, 1997
- Multidrug-Resistant Tuberculosis in Patients without HIV InfectionNew England Journal of Medicine, 1995
- Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and RifampinNew England Journal of Medicine, 1993
- INFLUENCE OF INITIAL-DRUG RESISTANCE ON THE RESPONSE TO SHORT-COURSE CHEMOTHERAPY OF PULMONARY TUBERCULOSISPublished by Elsevier ,1986